Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix (TSXV:HEM) signs services agreement with My Next Health

Brieanna McCutcheon  January 21, 2022

Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics

Newsfile January 21, 2022

Hemostemix (TSXV:HEM) combining ACP-01 with stem cells for diabetes

Caroline Egan  January 11, 2022

Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes

Newsfile January 11, 2022

Virtual Conference for Life Sciences Companies Broadcast Live December 16th

PR Newswire December 14, 2021

Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th

PR Newswire December 9, 2021

Hemostemix Announces Soft Lock of Database as Source Document Verification Completed

Newsfile December 9, 2021

Hemostemix Confirms OTCQB Listing

Newsfile October 28, 2021

How a clinical-stage biotech company could become the first to commercialize cell therapy for critical limb ischemia

Jocelyn Aspa October 25, 2021

Hemostemix Confirms OTCQB Application is Filed

Newsfile October 19, 2021

Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer

Newsfile October 14, 2021

Hemostemix Inc. (TSXV:HEM) shares second stem cell recipient interview results

Caroline Egan  October 4, 2021

Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain

Newsfile October 4, 2021

Hemostemix (TSXV:HEM) closes the first tranche of its private placement

John Ballem  September 21, 2021

Hemostemix Announces Closing of First Tranche of Unit Private Placement

Newsfile September 21, 2021

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Newsfile September 14, 2021

Hemostemix Announces Five Million Unit Private Placement

Newsfile September 8, 2021

Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results

Newsfile July 6, 2021

Hemostemix Announces Warrant Repricing and Extension

Newsfile July 5, 2021

Peter Lacey Increases His Investment in Hemostemix Inc.

Newsfile June 21, 2021